Saint Joseph's Hospital of Atlanta is seeking to become the Atlanta Regional Community Clinical Oncology Program (CCOP). As a CCOP, our organization will coordinate and expand existing resources to support the development of a community clinical research program. Through our primary research bases, SWOG, RTOG, and M.D. Anderson Hospital, the CCOP will offer participants access to current clinical trials. The CCOP will also formalize and expand existing cancer control activities and enhance Saint Joseph's potential as a resource for future NCI cancer control research studies. We seek to increase the involvement of primary care physicians in the cancer program and make them aware of the availability of existing protocols. The Atlanta Regional CCOP will continue to develop and refine a complete data management system to assure the collection, quality control and timely transmission of data to the research bases. We will maintain and expand the clinical research quality control program to assure submission of the highest quality protocol data to the research bases. Protocol selection procedures will be maintained and refined, under CCOP, so as to avoid conflicts between protocols and define a sufficient population in order to participate in those studies identified as high priority by the research bases. The CCOP will maintain implemented standards of participation for investigators and continue to enforce a complete set of policies and procedures for the management of investigational drugs. In essence, the CCOP will expand a strong community cancer program which will support the clinical and cancer control research efforts of investigators. Our goals parallel those of the NCI, provide support for community clinical research efforts, stimulate quality care through participation in protocol studies, and foster a community cancer network among the NCI, cooperative groups and Saint Joseph's.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045450-03
Application #
3558627
Study Section
(SRC)
Project Start
1987-08-01
Project End
1990-05-31
Budget Start
1989-06-12
Budget End
1990-05-31
Support Year
3
Fiscal Year
1989
Total Cost
Indirect Cost
Name
St. Joseph's Hospital (Atlanta)
Department
Type
DUNS #
City
Atlanta
State
GA
Country
United States
Zip Code
30342
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Friedberg, Jonathan W; Unger, Joseph M; Burack, W Richard et al. (2014) R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. Br J Haematol 166:382-9
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33

Showing the most recent 10 out of 52 publications